Every transparent pharmacy benefits manager (PBM) claims to save your clients money. With a pass-through contract, the vendor earns a flat, disclosed administrative fee instead of keeping the spread between what it charges the plan and what it pays the pharmacy. Rebates flow to the plan sponsor and nothing hides in the margins.
That structural change removes a built-in conflict of interest. But it doesn’t automatically lower pharmacy costs. Two vendors with identical pass-through contracts can produce very different results. What separates them isn’t pricing structure. It’s execution: whether they can find savings, act on them, and prove the results.
So what actually separates the vendors that deliver from the ones that disappoint? Here are the five differentiators that matter:
1. Savings execution. Data access is a starting point, not an outcome. What matters is the full pipeline: identify an opportunity, recommend a specific intervention with a dollar impact, get employer approval, implement, and track actual savings against projection. Ask a vendor to walk you through one real example, start to finish, with the actual result.
2. Clinical depth. This is the single most important differentiator. Fewer than 2% of prescription claims likely account for more than 50% of total pharmacy spend, and a single specialty drug can add more than $250,000 a year to plan costs. A pharmacist who proactively reviews high-cost claims and steers members toward clinically equivalent alternatives protects spend better than any unit-cost discount. Ask whether real clinicians review prior authorizations, or whether an automated system handles them.
3. Channel optimization. Some of the largest per-claim savings come from directing members to the right dispensing channel: alternative specialty channels, manufacturer copay assistance programs, and mail order where appropriate. Ask for documented enrollment completion rates, not a description of the capability.
4. Implementation quality. Most implementation failures are predictable. Late ID cards, claims rejections at cutover, and specialty therapy disruptions all trace back to weak planning. Ask who owns your implementation by name, and whether that person remains your contact after go-live.
5. Service durability. Service failures, not pricing problems, are the most common reason clients end up frustrated. When account managers turn over, institutional knowledge walks out the door. Ask how many clients your account manager supports and what the team’s average tenure is.
Treat RFP Projections as Estimates, Never Guarantees
A savings projection in an RFP is an estimate built on static assumptions. Drug mix and utilization will change after go-live. Never present a projection as a commitment unless the contract explicitly guarantees it in writing.
A few points worth setting straight with your clients before anything is signed:
- A disclosed rate isn’t necessarily a competitive one.
- A large rebate doesn’t always mean lower net cost. A drug with a smaller rebate and a lower list price can cost the plan less than a high-list-price drug with a big rebate.
- Audit rights in a contract aren’t the same as usable audit access. If a vendor can’t run a live, claim-level audit during your evaluation, that’s a red flag.
Watch for These Four Failure Patterns
The most common disappointments share one root cause: someone treated a structural feature of the contract as an outcome. Three patterns show up again and again.
- The visibility trap. Better data lands on a team that can’t act on it. Data doesn’t lower costs. Action does.
- Rebate math that doesn’t hold. Post-go-live rebates come in smaller than projected because of gross-to-net dynamics. The proposal savings never show up in results.
- Formulary disruption without savings. Members experience coverage changes, but plan costs don’t drop. The disruption is real. The benefit isn’t.
- Guarantees with too many outs. The savings guarantee sounds strong, but exclusions, assumptions, and contract caveats may actually impact results. The reassurance is real. The protection isn’t.
The Bottom Line
Transparency is the price of entry, not the finish line. The advisors who consistently make strong recommendations evaluate execution, not just pricing structure. They stay engaged after go-live, hold vendors accountable, and guide their clients through years two and three – when savings either materialize or don’t.
